We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TriLink BioTechnologies Logo

TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, nucleoside triphosphates and mRNA capping analogs. They has scale-up expertise and unique mRNA, oligonucleotide and plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.

Latest TriLink BioTechnologies Content

A visual zoomed in representation of a mRNA cap
Whitepaper

The Economics of Synthetic mRNA Capping Strategies

This whitepaper evaluates the results of a study into the three main capping options available to manufacturers, highlighting expert insights on mRNA capping costs and customer needs.
An RNA strand.
Product News

TriLink BioTechnologies Collaborates With Johns Hopkins University To Establish a New RNA Innovation Center

The collaborative center will help to lower barriers to RNA innovation and discovery.
A strand of mRNA.
Product News

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) has announced the grand opening of its new cGMP mRNA manufacturing facility.
A scientist holding a vial.
Product News

TriLink BioTechnologies® Solidifies IP Position With Awarded Patents for CleanCap® Capping Technology in China and Canada

TriLink’s CleanCap® capping technology is patented globally & TriLink is the sole authorized manufacturer of CleanCap® capping analogs
Oversized syringe containing a vaccine being injected into the world.
Article

Next-Gen mRNA Technology: A Crucial Pandemic Preparedness Tool

Drew Burch discusses how next-gen mRNA technology is one of the most valuable tools to combat and control disease outbreaks and why continued investment in this field is crucial for maintaining our pandemic preparedness.
TriLink Biotechnologies logo.
Product News

TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion As mRNA Manufacturing Facility Nears Completion

TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.
Advertisement